Kryza, Thomas http://orcid.org/0000-0003-1668-8551
Khan, Tashbib http://orcid.org/0000-0001-5203-0672
Lovell, Scott
Harrington, Brittney S. http://orcid.org/0000-0001-7083-069X
Yin, Julia http://orcid.org/0000-0002-7706-5895
Porazinski, Sean
Pajic, Marina
Koistinen, Hannu http://orcid.org/0000-0003-0926-3109
Rantala, Juha K. http://orcid.org/0000-0002-4999-5585
Dreyer, Tobias
Magdolen, Viktor
Reuning, Ute
He, Yaowu http://orcid.org/0000-0002-7828-263X
Tate, Edward W. http://orcid.org/0000-0003-2213-5814
Hooper, John D. http://orcid.org/0000-0003-1054-8486
Funding for this research was provided by:
Philip Hemstritch Fellowship in pancreatic cancer
Sigrid Juselius Foundation
German Academic Exchange Service
Cancer Council Queensland (APP1082040)
Article History
Received: 14 October 2020
Accepted: 4 March 2021
First Online: 15 April 2021
Competing interests
: E.W.T. is a founder, Director and shareholder in Myricx Pharma Ltd (UK). No potential conflicts of interest were disclosed by the other authors.